摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

trans-(4-{4-[3-(trifluoromethyl)phenyl]imidazol-2-yl}cyclohexyl)methylamine | 519058-34-5

中文名称
——
中文别名
——
英文名称
trans-(4-{4-[3-(trifluoromethyl)phenyl]imidazol-2-yl}cyclohexyl)methylamine
英文别名
——
trans-(4-{4-[3-(trifluoromethyl)phenyl]imidazol-2-yl}cyclohexyl)methylamine化学式
CAS
519058-34-5
化学式
C17H20F3N3
mdl
——
分子量
323.361
InChiKey
VEGIHKMKYLZPBC-HAQNSBGRSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.33
  • 重原子数:
    23.0
  • 可旋转键数:
    3.0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.47
  • 拓扑面积:
    54.7
  • 氢给体数:
    2.0
  • 氢受体数:
    2.0

反应信息

  • 作为反应物:
    描述:
    trans-(4-{4-[3-(trifluoromethyl)phenyl]imidazol-2-yl}cyclohexyl)methylaminesodium hexamethyldisilazane三乙胺 作用下, 以 四氢呋喃二氯甲烷 为溶剂, 反应 2.08h, 生成 N-Methyl-N-{4-[4-(3-trifluoromethyl-phenyl)-1H-imidazol-2-yl]-cyclohexylmethyl}-benzenesulfonamide
    参考文献:
    名称:
    Design, Synthesis, and Biological Evaluation of Substituted 2-Cyclohexyl-4-phenyl-1H-imidazoles:  Potent and Selective Neuropeptide Y Y5-Receptor Antagonists
    摘要:
    Antagonizing the robust stimulation of food intake by neuropeptide Y represents a new potential therapeutic approach for the treatment of obesity. Earlier pharmacological studies have pointed to the Y1 and Y5 receptors as the most likely mediators of the NPY orexigenic response. In this paper, we describe a new series of small molecule Y5 antagonists derived from a 2,4diaryl-1H-imidazole lead. The main objectives of our structural optimization efforts were to produce novel and potent Y5 antagonists with an improved oral pharmacokinetic profile and less affinity for the hERG potassium channel compared to the lead 2,4-diarylimidazole structures. These goals were accomplished by replacement of the 2-aryl ring with a cyclohexyl ring and subsequent elaboration of the 4-position of the cyclohexyl ring with a variety of hydrophilic functionalities. The resulting compound, N-(2-hydroxy-tert-butyl)(4-{4-[3-(trifluoro-methyl)phenyl]imidazol-2-yl}cyclohexyl)carboxamide (20), displayed good potency at the Y5 receptor (K-i = 3 nM), while interactions at the hERG channel were essentially eliminated (6% inhibition at a concentration of 3 muM). Importantly, the pharmacokinetic properties of 20 (F = 36%) represented a marked improvement over that of the initial 2,4-diarylimidazole structures.
    DOI:
    10.1021/jm030490g
  • 作为产物:
    描述:
    trans-4-{[(phenylmethoxy)carbonylamino]methyl}cyclohexanecarboxylic acid 在 palladium on activated charcoal ammonium acetate 、 氢气 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 溶剂黄146三乙胺 作用下, 以 乙醇N,N-二甲基甲酰胺 为溶剂, 80.0 ℃ 、379.21 kPa 条件下, 反应 16.0h, 生成 trans-(4-{4-[3-(trifluoromethyl)phenyl]imidazol-2-yl}cyclohexyl)methylamine
    参考文献:
    名称:
    Design, Synthesis, and Biological Evaluation of Substituted 2-Cyclohexyl-4-phenyl-1H-imidazoles:  Potent and Selective Neuropeptide Y Y5-Receptor Antagonists
    摘要:
    Antagonizing the robust stimulation of food intake by neuropeptide Y represents a new potential therapeutic approach for the treatment of obesity. Earlier pharmacological studies have pointed to the Y1 and Y5 receptors as the most likely mediators of the NPY orexigenic response. In this paper, we describe a new series of small molecule Y5 antagonists derived from a 2,4diaryl-1H-imidazole lead. The main objectives of our structural optimization efforts were to produce novel and potent Y5 antagonists with an improved oral pharmacokinetic profile and less affinity for the hERG potassium channel compared to the lead 2,4-diarylimidazole structures. These goals were accomplished by replacement of the 2-aryl ring with a cyclohexyl ring and subsequent elaboration of the 4-position of the cyclohexyl ring with a variety of hydrophilic functionalities. The resulting compound, N-(2-hydroxy-tert-butyl)(4-{4-[3-(trifluoro-methyl)phenyl]imidazol-2-yl}cyclohexyl)carboxamide (20), displayed good potency at the Y5 receptor (K-i = 3 nM), while interactions at the hERG channel were essentially eliminated (6% inhibition at a concentration of 3 muM). Importantly, the pharmacokinetic properties of 20 (F = 36%) represented a marked improvement over that of the initial 2,4-diarylimidazole structures.
    DOI:
    10.1021/jm030490g
点击查看最新优质反应信息